“Hormonal Wedge Resection”: An Effective Treatment Method of Anovulatory Infertility Associated with Polycystic Ovary Syndrome

  • György Siklósi


The greatest contradiction in the CC treatment of polycystic ovary syndrome is that – even with permeable fallopian tube and normospermia – despite achieving 70–80 % actual ovulation, only 30–40 % of patients will conceive. The diagnostic method we developed made it evident that different levels of insufficient folliculo-luteal function (FLF) underlie this observation and the high prevalence of clinical abortion (~30 %) in patients. After normalising FLF, ovulatory and pregnancy rates became almost equal.

We developed an effective method, which we called “hormonal wedge resection”, to cure anovulatory infertility associated with PCOS. This was inspired by our observation that when dexamethasone (DEX) treatment (0.5 mg/day) is continued after the combined suppression of the adrenal cortex and the ovaries (oestrogen-gestagen + DEX), ovarian hyperandrogenism does not recur (or only recurs after a long time). DEX treatment combined with the appropriate dose of CC – together with the control of luteal progesterone (P) – resulted in ovulation in 97.6 % of patients (120/123), and 95.9 % (118/123) became pregnant 167 times (with at least one permeable fallopian tube and normospermia).

During hormonal wedge resection therapy, every pregnancy occurred within 1–7 months with physiological FLF (N = 111, P > 23 ng/ml), the average monthly pregnancy rate was 38.6 % (!), the cumulative pregnancy rate was 95.5 % and the time to pregnancy was 2.44 ± 1.3 cycles. Pregnancy outcome was also favourable with physiological FLF: miscarriage occurred in 2.7 % of cases, preterm birth in 1 % and IUGR in 1 %, and there were no cases of preeclampsia. Twin births took place in 9.3 % of patients. Concerning pregnancy outcome, the most optimal P value appears to be the average of 26–32 ng/ml: average singular newborn weight is 3,716 g, length 56 cm, weight percentile 75 % and length percentile 73 %, and the incidence of twin births is 5.6 %.

Hormonal wedge resection proved to be an effective, simple, repeatable and low-cost therapy for anovulatory infertility associated with PCOS, and it is also suitable for treating CC-resistant cases.


Preterm Birth Adrenal Cortex Polycystic Ovary Syndrome Clomiphene Citrate PCOS Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adashi EY, Rock JA, Guzick D, Wentz AC, Jones GS, Jones HW. Fertility following bilateral ovarian wedge resection: a critical analysis of 90 consecutive cases of the polycystic ovary syndrome. Fertil Steril. 1981;36:320–5.CrossRefPubMedGoogle Scholar
  2. ASRM 2012 – Diagnostic evaluation of the infertile female: a committee opinion. Practice Committee of American Society for Reproductive Medicine. Fertil Steril. 2012a;98:302–7.Google Scholar
  3. ASRM 2012. – The clinical relevance of luteal phase deficiency: a committee opinion. The Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2012b;98:1112–7.Google Scholar
  4. ASRM-ESHRE 2012 – Luca Gianaroli, M, Catherine Racowsky, Joep Geraedts, Marcelle Cedars, Antonis Makrigiannakis, Roger A. Lobo. Best practices of ASRM and ESHRE: a journey through reproductive medicine. Fertil Steril. 2012;98:1380–94.Google Scholar
  5. Badawy A, Mosbah A, Tharwat A, Eid M. Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. Fertil Steril. 2009;92:236–9.CrossRefPubMedGoogle Scholar
  6. Barbarino A, De Marinis L, Tofani A, et al. Corticotropin-releasing hormone inhibition of gonadotropin release and the effect of opioid blockade. J Clin Endocrinol Metab. 1989;68:523–8.CrossRefPubMedGoogle Scholar
  7. Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci. 2014;6:104–19.Google Scholar
  8. Berger JJ, Bates Jr GW. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health. 2014;13(6):613–21.Google Scholar
  9. Bozdag G, Yildiz BO. Combined oral contraceptives in polycystic ovary syndrome – indications and cautions. Front Horm Res. 2013;40:115–27.CrossRefPubMedGoogle Scholar
  10. Buttram VC, Vaquero C. Post ovarian wedge resection adhesive disease. Fertil Steril. 1975;26:874–8.CrossRefPubMedGoogle Scholar
  11. Chatterton Jr RT, Kazer RR, Rebar RW. Depletion of luteal phase serum progesterone during constant infusion of cortisol phosphate in the cynomolgus monkey. Fertil Steril. 1991;56:547–54.CrossRefPubMedGoogle Scholar
  12. Coney P. Polycystic ovarian disease: current concepts of pathophysiology and therapy. Fertil Steril. 1984;42(5):667–82.CrossRefPubMedGoogle Scholar
  13. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz B, ESE PCOS Special Interest Group. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group’s Questionnaire. Eur J Endocrinol. 2014;171(4):489–98.CrossRefPubMedGoogle Scholar
  14. Dickey RP, Taylor SN, Rye PH, Lu PY. Future use of clomiphene in ovarian stimulation. A role for clomiphene in the 21st century? Hum Reprod. 1998;13(9):2361–2.CrossRefPubMedGoogle Scholar
  15. Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006;21:1805–8.CrossRefPubMedGoogle Scholar
  16. ESHRE/ASRM 2003 – Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Hum Reprod. 2004;19(1):41–7.Google Scholar
  17. ESHRE/ASRM 2007 – Geisthövel F, Rabe T. The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS) – an extended critical analysis. Reprod Biomed Online. 2007;14(4):522–35.Google Scholar
  18. ESHRE/ASRM 2008 – Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89(3):505–22.Google Scholar
  19. ESHRE/ASRM 2013 – Panidis D, Tziomalos K, Papadakis E, Kandaraki EA, Katsikis I. The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. Hormones (Athens). 2013;12(2):192–200.Google Scholar
  20. Ferriman D, Gallwey JP. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–6.Google Scholar
  21. Homburg R, Giudice LC, Chang RJ. Polycystic ovary syndrome. Hum Reprod. 1996;11(3):465–6.CrossRefGoogle Scholar
  22. Isaacs Jr JD, Lincoln SR, Cowan BD. Extended clomiphene citrate (CC) and prednisone for the treatment of chronic anovulation resistant to CC alone. Fertil Steril. 1997;67:641–3.CrossRefPubMedGoogle Scholar
  23. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H, NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014a;371:119–29.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Legro RS, Zhang H, Eunice Kennedy Shriver NICHD Reproductive Medicine Network. Letrozole or clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014b;371:1463–4.CrossRefPubMedGoogle Scholar
  25. Martikainen H, Salmela P, Nuojua-Huttunen S, Perälä J, Leinonen S, Knip M, Ruokonen A. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertil Steril. 1996;66:564–70.CrossRefPubMedGoogle Scholar
  26. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332(7556):1485.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Monzani A, Petraglia F, De Leo V, Fabbri G, D’Ambrogio G, Volpe A, Genazzani AR. Glucocorticoids but not vasopressin or oxytocin inhibit luteinizing hormone secretion in patients with psychogenic amenorrhea. Gynecol Endocrinol 1989;3:55–62.Google Scholar
  28. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med. 2008a;358:47–54.CrossRefPubMedGoogle Scholar
  29. Nestler JE. Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective. Fertil Steril. 2008b;90(1):14–6.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril. 2002;78:1001–4.CrossRefPubMedGoogle Scholar
  31. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;18(6):1–13.CrossRefGoogle Scholar
  32. Veltman-Verhulst SM, van Rijn BB, Westerveld HE, Franx A, Bruinse HW, Fauser BC, Goverde AJ. Polycystic ovary syndrome and early-onset preeclampsia: reproductive manifestations of increased cardiovascular risk. Menopause. 2010;17(5):990–6.CrossRefPubMedGoogle Scholar
  33. Whirledge S, Cidlowski JA. A role for glucocorticoids in stress-impaired reproduction: beyond the hypothalamus and pituitary. Endocrinology. 2013;154:4450–68.Google Scholar
  34. Wildt L, Leyendecker G, Sirpetermann T, Waibeltreber S. Treatment with naltrexone in hypothalamic ovarian failure – induction of ovulation and pregnancy. Hum Reprod. 1993;8:350–8.CrossRefPubMedGoogle Scholar
  35. Yen SSC, Chang C, Judd HL. Functional aberrations of the hypothalamic-pituitary system in polycystic ovary syndrome: a consideration of the pathogenesis. In: James VHT, Serio M, Giusti G, editors. The endocrine function of the human ovary. London/New York/San Francisco: Academic Press; 1976. p. 373–85.Google Scholar
  36. Yen SSC. The polycystic ovary syndrome. Clin Endocrinol. 1980;12:177–83.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • György Siklósi
    • 1
  1. 1.Semmelweis University Second Department of Obstetrics and GynecologyBudapestHungary

Personalised recommendations